Skip to main content

Table 1 Characteristics of the study population

From: A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women

  Controls (n = 4687) Cases (n = 3663)
  Frequency Mean (SD) or % Frequency Mean (SD) or %
Age at enrollment (years) 4687 55.62 (12.01) 3663 54.94 (11.74)
Age at enrollment (years)
 18–29 24 0.51 30 0.82
 30–39 396 8.45 306 8.35
 40–49 1107 23.62 945 25.8
 50–59 1461 31.17 1087 29.68
 60–69 986 21.04 819 22.36
 70–79 609 12.99 433 11.82
 80+ 104 2.22 43 1.17
DNA source
 Blood 1817 38.77 1961 53.54
 Mouthwash 2243 47.86 853 23.29
 Saliva 627 13.38 849 23.18
Study
 BWHS 2249 48.98 901 24.6
 WCHS 834 17.79 821 22.41
 CBCS 615 13.12 1408 38.44
 MEC 989 21.1 533 14.55
Location
 New Jersey (NJ) 573 12.23 613 16.73
 Northeast (except NJ) 1245 26.56 441 12.04
 South 1476 31.49 1720 46.96
 Midwest 238 5.08 200 5.46
 West 1155 24.64 689 18.81
Stage
 In situ NA   376 10.26
 Invasive NA   2528 69.01
 Unknown NA   759 20.72
Tumor receptor status
 ER
  Positive NA   1983 54.14
  Negative NA   1098 29.98
  Unknown NA   582 15.89
 PR
  Positive NA   1580 43.13
  Negative NA   1343 36.66
  Unknown NA   740 20.2
 HER2
  Positive NA   344 9.39
  Negative NA   1356 37.02
  Unknown NA   1963 53.59
 Triple negative
  Yes NA   405 11.06
  No NA   1613 44.03
  Unknown NA   1645 44.91
  1. BWHS, Black Women’s Health Study; CBCS, Carolina Breast Cancer Study; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MEC, Multiethnic Cohort; NA, not applicable; PR, progesterone receptor; SD, standard deviation; WCHS, Women’s Circle of Health Study